Seizures
2 original drugs 2
Novel Drugs
11
Reformulations
0
Active Trials
5
Drug Targets
Phase 3 Readouts Pro
12 active Phase 3 trials with confidence-graded completion dates.
Q1 2027
40 mg/day vormatrogine for 12 weeks
Praxis Precision Medicines
Estimated · fresh NCT07505004
Unlock 9 more readouts with confidence-graded estimates
Upgrade to Pro Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Treatments by Mechanism
Top 12 mechanisms across 97 industry trials with a known mechanism of action.
Epoxide Hydrolase Inhibitors [MoA]
17 trials 2 active 6 sponsors
Sodium Channel Antagonists [MoA]
5 trials 2 active 2 sponsors
5-HT2 receptor
1 trials 1 active 1 sponsor
Voltage-gated sodium channels
28 trials 9 sponsors
Anti-epileptic Agent
14 trials 6 sponsors
SV2A
11 trials 7 sponsors
Noncompetitive AMPA Glutamate Receptor Antagonist
10 trials 3 sponsors
alpha 2 -delta site
3 trials 1 sponsor
Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator
3 trials 1 sponsor
Cytochrome P450 3A4 Inducers [MoA]
2 trials 1 sponsor
Benzodiazepine
2 trials 2 sponsors
Integrin Receptor Antagonist
1 trials 1 sponsor
MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.
Clinical Pipeline by Phase
296 industry-sponsored trials across 83 sponsors
Showing 19 of 19 trials
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| Azurity Pharmaceuticals | Zonisamide Oral Product | — | NOT YET RECRUITING | 2027-09 | NCT06534502 |
| Eisai Korea Inc. | Perampanel | Noncompetitive AMPA Glutamate Receptor Antagonist [EPC] | COMPLETED | 2025-01-23 | NCT05533814 |
| Eisai Inc. | Perampanel | Noncompetitive AMPA Glutamate Receptor Antagonist [EPC] | COMPLETED | 2021-04-27 | NCT03288129 |
| Sumitomo Pharma America, Inc. | Eslicarbazepine acetate | Voltage-gated sodium channels | COMPLETED | 2019-06-06 | NCT03116828 |
| Hamad Medical Corporation | Buccal midazolam | — | COMPLETED | 2018-11 | NCT02897856 |
| Eisai Korea Inc. | Perampanel | Noncompetitive AMPA Glutamate Receptor Antagonist [EPC] | COMPLETED | 2018-04-26 | NCT02726074 |
| GSK | Lamotrigine tablets 25/100 mg | — | COMPLETED | 2015-05-11 | NCT02100644 |
| UCB Korea Co., Ltd. | Levetiracetam | SV2A | COMPLETED | 2015-05 | NCT01229735 |
| Korea UCB Co., Ltd. | Levetiracetam | SV2A | COMPLETED | 2014-07 | NCT01498822 |
| Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Pregabalin | alpha 2 -delta site | COMPLETED | 2013-07 | NCT00537940 |
| Johnson & Johnson Taiwan Ltd | Topiramate add-on therapy | — | COMPLETED | 2011-01 | NCT01627860 |
| Eisai Korea Inc. | zonisamide | Anti-epileptic Agent [EPC] | COMPLETED | 2010-08-31 | NCT01140867 |
| Johnson & Johnson | Topiramate | Cytochrome P450 3A4 Inducers [MoA] | COMPLETED | 2010-01-19 | NCT01689649 |
| Eisai Inc. | Zonisamide | Anti-epileptic Agent [EPC] | COMPLETED | 2009-09 | NCT00659958 |
| Eisai Limited | Zonisamide | Anti-epileptic Agent [EPC] | COMPLETED | 2008-12 | NCT00713622 |
| GSK | ezogabine/retigabine | — | TERMINATED | 2016-11-16 | NCT01607346 |
| GSK | Ezogabine/Retigabine IR | — | TERMINATED | 2013-06-20 | NCT01721317 |
| Eisai Limited | Zonisamide at targeted daily doses of 100-500 mg/day | — | TERMINATED | 2010-11 | NCT01546688 |
| Eisai Inc. | Perampanel | Noncompetitive AMPA Glutamate Receptor Antagonist [EPC] | WITHDRAWN | 2016-08 | NCT02220972 |
Showing 100 of 128 trials (top 100 by completion date — export for full list)
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| UCB Biopharma SRL | Staccato alprazolam | — | RECRUITING | 2026-06-30 | NCT05077904 |
| Xenon Pharmaceuticals Inc. | XEN1101 | — | RECRUITING | 2026-10 | NCT05716100 |
| Biohaven Therapeutics Ltd. | BHV-7000 | — | RECRUITING | 2026-12 | NCT06132893 |
| Praxis Precision Medicines | 40 mg/day vormatrogine for 12 weeks | — | RECRUITING | 2027-01 | NCT07505004 |
| Ono Pharmaceutical Co., Ltd. | Cenobamate | Sodium Channel Antagonists [MoA] | RECRUITING | 2027-01-31 | NCT06579573 |
| SK Life Science, Inc. | Carisbamate | — | RECRUITING | 2027-02 | NCT05219617 |
| Ono Pharmaceutical Co., Ltd. | Cenobamate (tablet) for 12 to < 18 year olds | — | RECRUITING | 2028-03-30 | NCT07594158 |
| Neurona Therapeutics | NRTX-1001 | — | RECRUITING | 2029-02 | NCT05135091 |
| Rapport Therapeutics Inc. | RAP-219 | — | RECRUITING | 2029-07 | NCT07563881 |
| UCB Biopharma SRL | Brivaracetam Film-coated tablet | — | RECRUITING | 2030-03-01 | NCT06315322 |
| UCB Biopharma SRL | Brivaracetam | Epoxide Hydrolase Inhibitors [MoA] | RECRUITING | 2030-07-08 | NCT04715646 |
| Biohaven Therapeutics Ltd. | BHV-7000 | — | RECRUITING | 2026-05 | NCT06309966 |
| UCB Biopharma SRL | Brivaracetam | Epoxide Hydrolase Inhibitors [MoA] | ACTIVE NOT RECRUITING | 2026-08-24 | NCT04666610 |
| SK Life Science, Inc. | Xcopri | Sodium Channel Antagonists [MoA] | ACTIVE NOT RECRUITING | 2026-11 | NCT05067634 |
| Zogenix, Inc. | Fenfluramine | 5-HT2 receptor | ACTIVE NOT RECRUITING | 2027-11-08 | NCT05064878 |
| NeuroPace | — | — | ACTIVE NOT RECRUITING | 2025-04-04 | NCT05147571 |
| Rapport Therapeutics Inc. | RAP-219 | — | NOT YET RECRUITING | 2029-07 | NCT07594119 |
| Xenon Pharmaceuticals Inc. | XEN1101 | — | COMPLETED | 2026-01-12 | NCT05614063 |
| SK Life Science, Inc. | Cenobamate | Sodium Channel Antagonists [MoA] | COMPLETED | 2025-05-26 | NCT03678753 |
| UCB Biopharma SRL | Brivaracetam Film-coated tablet | — | COMPLETED | 2025-03-18 | NCT05109234 |
| UCB Biopharma SRL | Lacosamide | Voltage-gated sodium channels | COMPLETED | 2025-02-12 | NCT04627285 |
| UCB Biopharma SRL | Brivaracetam | Epoxide Hydrolase Inhibitors [MoA] | COMPLETED | 2024-12-24 | NCT03250377 |
| Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Brivaracetam | Epoxide Hydrolase Inhibitors [MoA] | COMPLETED | 2024-05-21 | NCT07563634 |
| UCB BIOSCIENCES, Inc. | Lacosamide Tablet | — | COMPLETED | 2023-03-30 | NCT02408549 |
| UCB Biopharma SRL | Brivaracetam | Epoxide Hydrolase Inhibitors [MoA] | COMPLETED | 2022-06-30 | NCT03083665 |
| UCB BIOSCIENCES, Inc. | Lacosamide | Voltage-gated sodium channels | COMPLETED | 2022-04-13 | NCT01964560 |
| UCB Pharma SA | Brivaracetam (BRV) | — | COMPLETED | 2022-02-03 | NCT01364597 |
| Jazz Pharmaceuticals | GWP42003-P | — | COMPLETED | 2021-06-11 | NCT02544750 |
| SK Life Science, Inc. | YKP3089 | — | COMPLETED | 2021-03-31 | NCT02535091 |
| UCB Biopharma S.P.R.L. | Brivaracetam | Epoxide Hydrolase Inhibitors [MoA] | COMPLETED | 2021-03-27 | NCT03685630 |
| GW Research Ltd | GWP42003-P | — | COMPLETED | 2020-09-24 | NCT02224573 |
| Aquestive Therapeutics | Diazepam Buccal Soluble Film 5, 7.5,10, 12.5,15 or 17.5 mg with individual dose determined according to age and weight category | — | COMPLETED | 2020-06-25 | NCT03428360 |
| Neurelis, Inc. | NRL-1 | — | COMPLETED | 2020-06-17 | NCT02721069 |
| UCB BIOSCIENCES, Inc. | Lacosamide | Voltage-gated sodium channels | COMPLETED | 2020-05-28 | NCT02477839 |
| Johnson & Johnson | Topiramate | Cytochrome P450 3A4 Inducers [MoA] | COMPLETED | 2020-04-30 | NCT02201251 |
| UCB Biopharma S.P.R.L. | Lacosamide | Voltage-gated sodium channels | COMPLETED | 2020-01 | NCT02582866 |
| Nobelpharma | Oxcarbazepine | Anti-epileptic Agent [EPC] | COMPLETED | 2019-09-30 | NCT01051193 |
| Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Pregabalin | alpha 2 -delta site | COMPLETED | 2019-08-22 | NCT01463306 |
| UCB Pharma SA | Lacosamide | Voltage-gated sodium channels | COMPLETED | 2019-07-31 | NCT01832038 |
| UCB BIOSCIENCES, Inc. | Lacosamide | Voltage-gated sodium channels | COMPLETED | 2019-06-28 | NCT02710890 |
| UCB BIOSCIENCES, Inc. | Brivaracetam | Epoxide Hydrolase Inhibitors [MoA] | COMPLETED | 2019-04-18 | NCT01339559 |
| UCB BIOSCIENCES, Inc. | Lacosamide Tablet | — | COMPLETED | 2019-04 | NCT02408523 |
| Eisai Co., Ltd. | E2007 | — | COMPLETED | 2019-02-28 | NCT03201900 |
| Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Pregabalin Dose Level 1 | — | COMPLETED | 2019-02-20 | NCT01747915 |
| Jazz Pharmaceuticals | GWP42003-P | — | COMPLETED | 2019-01-22 | NCT02544763 |
| Bial - Portela C S.A. | ESL 800 mg | — | COMPLETED | 2018-09-11 | NCT02484001 |
| Jazz Pharmaceuticals | GWP42003-P | — | COMPLETED | 2018-04-09 | NCT02224703 |
| Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Pregabalin Dose Level 1 | — | COMPLETED | 2018-03-13 | NCT02072824 |
| UCB Japan Co. Ltd. | Lacosamide | Voltage-gated sodium channels | COMPLETED | 2017-11-21 | NCT02124564 |
| Novartis | RAD001 | — | COMPLETED | 2017-10-25 | NCT01713946 |
| INSYS Therapeutics Inc | Cannabidiol Oral Solution | — | COMPLETED | 2017-06-22 | NCT02318602 |
| Sumitomo Pharma America, Inc. | Eslicarbazepine acetate | Voltage-gated sodium channels | COMPLETED | 2017-04-15 | NCT00910247 |
| UCB Pharma | Brivaracetam | Epoxide Hydrolase Inhibitors [MoA] | COMPLETED | 2017-03 | NCT00761774 |
| UCB Pharma | Lacosamide | Voltage-gated sodium channels | COMPLETED | 2017-01-24 | NCT01921205 |
| UCB BIOSCIENCES GmbH | Lacosamide | Voltage-gated sodium channels | COMPLETED | 2017-01 | NCT01465997 |
| GSK | Retigabine IR | — | COMPLETED | 2016-12-14 | NCT01336621 |
| GSK | Retigabine IR | — | COMPLETED | 2016-12-14 | NCT01777139 |
| Eisai Co., Ltd. | Perampanel | Noncompetitive AMPA Glutamate Receptor Antagonist [EPC] | COMPLETED | 2016-09-21 | NCT02427607 |
| Bial - Portela C S.A. | Eslicarbazepine acetate (BIA 2-093) | — | COMPLETED | 2016-09 | NCT01162460 |
| Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Pregabalin add-on therapy | — | COMPLETED | 2016-08-10 | NCT01389596 |
| UCB Pharma SA | Brivaracetam | Epoxide Hydrolase Inhibitors [MoA] | COMPLETED | 2016-08 | NCT01728077 |
| Jazz Pharmaceuticals | GWP42003-P | — | COMPLETED | 2016-05-19 | NCT02224560 |
| UCB Pharma | Levetiracetam | SV2A | COMPLETED | 2016-04 | NCT01398956 |
| Jazz Pharmaceuticals | GWP42003-P 20 mg/kg/day Dose | — | COMPLETED | 2016-03-18 | NCT02224690 |
| Jazz Pharmaceuticals | GWP42003-P 20 mg/kg/day Dose | — | COMPLETED | 2015-11-26 | NCT02091375 |
| UCB Pharma SA | Levetiracetam | SV2A | COMPLETED | 2015-09 | NCT01954121 |
| UCB Biopharma S.P.R.L. | USL261 | — | COMPLETED | 2015-08 | NCT01999777 |
| UCB BIOSCIENCES GmbH | Lacosamide | Voltage-gated sodium channels | COMPLETED | 2015-07 | NCT01243177 |
| Ache Laboratorios Farmaceuticos S.A. | Levetiracetam | SV2A | COMPLETED | 2015-07 | NCT01392768 |
| UCB Pharma | Lacosamide | Voltage-gated sodium channels | COMPLETED | 2014-12 | NCT00530855 |
| UCB Japan Co. Ltd. | Lacosamide (200 mg/20 mL) | — | COMPLETED | 2014-10 | NCT02192814 |
| Eisai Inc. | perampanel | Noncompetitive AMPA Glutamate Receptor Antagonist [EPC] | COMPLETED | 2014-09 | NCT00735397 |
| UCB Pharma SA | Lacosamide 50 mg | — | COMPLETED | 2014-07 | NCT01710657 |
| UCB Pharma | Brivaracetam | Epoxide Hydrolase Inhibitors [MoA] | COMPLETED | 2014-05 | NCT01261325 |
| Upsher-Smith Laboratories | USL255 | — | COMPLETED | 2014-05 | NCT01191086 |
| UCB Japan Co. Ltd. | Levetiracetam | SV2A | COMPLETED | 2014-04 | NCT01228747 |
| GSK | Lamictal | Anti-epileptic Agent [EPC] | COMPLETED | 2014-02 | NCT01431976 |
| UCB Pharma | Lacosamide | Voltage-gated sodium channels | COMPLETED | 2013-12 | NCT01484977 |
| UCB Pharma SA | Brivaracetam | Epoxide Hydrolase Inhibitors [MoA] | COMPLETED | 2013-11 | NCT01653262 |
| Valexfarm | Remegal | — | COMPLETED | 2013-10 | NCT01749046 |
| UCB Japan Co. Ltd. | Levetiracetam (LEV) | — | COMPLETED | 2013-10 | NCT01506882 |
| Bial - Portela C S.A. | Eslicarbazepine Acetate | Voltage-gated sodium channels | COMPLETED | 2013-09 | NCT01422720 |
| UCB Japan Co. Ltd. | Levetiracetam | SV2A | COMPLETED | 2013-06 | NCT01292837 |
| Sumitomo Pharma America, Inc. | Eslicarbazepine acetate | Voltage-gated sodium channels | COMPLETED | 2013-05 | NCT00866775 |
| GSK | Lamictal | Anti-epileptic Agent [EPC] | COMPLETED | 2013-03 | NCT01431963 |
| Lundbeck LLC | Intravenous Carbamazepine (IV CBZ) | — | COMPLETED | 2013-01 | NCT01128959 |
| West-Ward Pharmaceutical | Phenobarbital | — | COMPLETED | 2013-01 | NCT01284556 |
| GSK | Retigabine IR | — | COMPLETED | 2012-12 | NCT01227902 |
| Upsher-Smith Laboratories | USL255 | — | COMPLETED | 2012-12 | NCT01142193 |
| Sumitomo Pharma America, Inc. | Eslicarbazepine acetate 1600 mg | — | COMPLETED | 2012-11 | NCT01091662 |
| Novartis | TRI476 | — | COMPLETED | 2012-10 | NCT00975715 |
| UCB Pharma | Brivaracetam tablets | — | COMPLETED | 2012-07 | NCT01405508 |
| Bial - Portela C S.A. | 800 mg QD Eslicarbazepine acetate | — | COMPLETED | 2012-01-12 | NCT00988429 |
| Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | pregabalin | alpha 2 -delta site | COMPLETED | 2011-12 | NCT00596466 |
| Supernus Pharmaceuticals, Inc. | Oxcarbazepine XR | — | COMPLETED | 2011-11 | NCT00908349 |
| Eisai Inc. | Zonisamide | Anti-epileptic Agent [EPC] | COMPLETED | 2011-06 | NCT00848549 |
| UCB Japan Co. Ltd. | Levetiracetam | SV2A | COMPLETED | 2011-04 | NCT01063764 |
| Eisai Inc. | Zonisamide | Anti-epileptic Agent [EPC] | COMPLETED | 2011-03 | NCT00566254 |
| SK Life Science, Inc. | carisbamate | — | COMPLETED | 2010-08 | NCT00744731 |
| UCB BIOSCIENCES, Inc. | lacosamide | Voltage-gated sodium channels | COMPLETED | 2010-06 | NCT00655486 |
Showing 97 of 97 trials
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| Supernus Pharmaceuticals, Inc. | SPN-817 | — | RECRUITING | 2026-10 | NCT06798896 |
| UniQure Biopharma B.V. | — | — | RECRUITING | 2026-11-30 | NCT06063850 |
| NaviFUS Corporation | — | — | RECRUITING | 2026-12-31 | NCT06388707 |
| Neurona Therapeutics | NRTX-1001 | — | RECRUITING | 2027-06-15 | NCT06422923 |
| Supernus Pharmaceuticals, Inc. | SPN-817 | — | RECRUITING | 2027-12-31 | NCT05518578 |
| Supernus Pharmaceuticals, Inc. | SPN-817 | — | RECRUITING | 2027-12-31 | NCT07141329 |
| Rapport Therapeutics Inc. | RAP-219 | — | RECRUITING | 2028-02-03 | NCT07219407 |
| Shanghai Zhimeng Biopharma, Inc. | CB03-154 | — | RECRUITING | 2029-01 | NCT07238868 |
| NeuroPro Therapeutics, Inc. | NPT 2042 | — | RECRUITING | 2026-03-30 | NCT06769659 |
| Bright Minds Biosciences Pty Ltd | BMB-101 | — | RECRUITING | 2025-09-15 | NCT06401538 |
| Praxis Precision Medicines | PRAX-222 - Initial Dose | — | RECRUITING | 2025-08 | NCT05737784 |
| Praxis Precision Medicines | 30mg PRAX-628 | — | RECRUITING | 2025-07 | NCT06908356 |
| NeuroPace | — | — | ACTIVE NOT RECRUITING | 2026-05-31 | NCT05339126 |
| Supernus Pharmaceuticals, Inc. | BIS-001ER | — | ACTIVE NOT RECRUITING | 2026-12-30 | NCT03474770 |
| Xenon Pharmaceuticals Inc. | XEN1101 | — | ACTIVE NOT RECRUITING | 2021-09-02 | NCT03796962 |
| Shanghai Zhimeng Biopharma, Inc. | Test drug CB03-154 5mg group | — | NOT YET RECRUITING | 2026-08 | NCT06612775 |
| Rapport Therapeutics Inc. | RAP-219 | — | COMPLETED | 2025-09-26 | NCT06377930 |
| Neurelis, Inc. | Diazepam Nasal Spray [Valtoco] | — | COMPLETED | 2025-03-11 | NCT05076838 |
| AbbVie | CVL-865 | — | COMPLETED | 2024-05-21 | NCT04244175 |
| Johnson & Johnson | JNJ-40411813 | — | COMPLETED | 2024-02-08 | NCT04836559 |
| Bial - Portela C S.A. | ESL 800 mg | — | COMPLETED | 2023-09-11 | NCT06597084 |
| Neurocrine Biosciences | NBI-921352 | — | COMPLETED | 2023-08-21 | NCT05159908 |
| Eisai Inc. | perampanel | Noncompetitive AMPA Glutamate Receptor Antagonist [EPC] | COMPLETED | 2022-08-23 | NCT02914314 |
| Cerebral Therapeutics LLC | Valproate | — | COMPLETED | 2021-06-01 | NCT02899611 |
| UCB BIOSCIENCES, Inc. | Lacosamide | Voltage-gated sodium channels | COMPLETED | 2021-05-18 | NCT00938912 |
| SK Life Science, Inc. | YKP3089 | — | COMPLETED | 2021-04-05 | NCT01866111 |
| Marinus Pharmaceuticals | Ganaxolone | Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator [EPC] | COMPLETED | 2021-01-19 | NCT03865732 |
| UCB Biopharma S.P.R.L. | Brivaracetam | Epoxide Hydrolase Inhibitors [MoA] | COMPLETED | 2020-11-04 | NCT03405714 |
| Takeda | TAK-935 | — | COMPLETED | 2020-06-09 | NCT03650452 |
| UCB Biopharma S.P.R.L. | Padsevonil | — | COMPLETED | 2020-01-30 | NCT03373383 |
| Aquestive Therapeutics | Diazepam Buccal Film | — | COMPLETED | 2020-01-28 | NCT03222349 |
| Biogen | Natalizumab | Integrin Receptor Antagonist [EPC] | COMPLETED | 2020-01-11 | NCT03283371 |
| Engage Therapeutics, Inc. | Staccato Alprazolam | — | COMPLETED | 2019-12-22 | NCT03478982 |
| Eisai Co., Ltd. | Perampanel | Noncompetitive AMPA Glutamate Receptor Antagonist [EPC] | COMPLETED | 2019-12-10 | NCT03754582 |
| Marinus Pharmaceuticals | IV Ganaxolone active | — | COMPLETED | 2019-09-18 | NCT03350035 |
| Aquestive Therapeutics | Diazepam Buccal Film | — | COMPLETED | 2019-07-31 | NCT03953820 |
| Jazz Pharmaceuticals | GWP42003-P | — | COMPLETED | 2019-05-27 | NCT02607904 |
| Jazz Pharmaceuticals | CX-8998 | — | COMPLETED | 2019-03-29 | NCT03406702 |
| Jazz Pharmaceuticals | GWP42003-P | — | COMPLETED | 2018-09-11 | NCT02607891 |
| Aquestive Therapeutics | Diazepam Buccal Film 12.5 mg | — | COMPLETED | 2018-07-25 | NCT03179891 |
| PhytoTech Therapeutics, Ltd. | PLT101 | — | COMPLETED | 2018-06-28 | NCT02987114 |
| UCB Biopharma S.P.R.L. | Brivaracetam | Epoxide Hydrolase Inhibitors [MoA] | COMPLETED | 2018-04-27 | NCT03021018 |
| Idorsia Pharmaceuticals Ltd. | ACT-709478 for oral use | — | COMPLETED | 2018-04-25 | NCT03239691 |
| UCB Pharma | Lacosamide | Voltage-gated sodium channels | COMPLETED | 2018-04-10 | NCT01969851 |
| Marinus Pharmaceuticals | Ganaxolone | Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator [EPC] | COMPLETED | 2018-01-16 | NCT02358538 |
| Jazz Pharmaceuticals | GWP42006 | — | COMPLETED | 2017-07 | NCT02365610 |
| Jazz Pharmaceuticals | GWP42003-P | — | COMPLETED | 2017-06-07 | NCT02564952 |
| UCB Biopharma S.P.R.L. | UCB0942 | — | COMPLETED | 2017-02 | NCT02495844 |
| Pfizer | PF-06372865 | — | COMPLETED | 2017-01-10 | NCT02564029 |
| Jazz Pharmaceuticals | GWP42003-P 20 mg/kg/Day Dose | — | COMPLETED | 2016-07-21 | NCT02565108 |
| Nova Pneuma Inc. | B=Inhaled Alprazolam 0.5 mg | — | COMPLETED | 2016-07 | NCT02351115 |
| INSYS Therapeutics Inc | Cannabidiol Oral Solution | — | COMPLETED | 2016-05-09 | NCT02324673 |
| Jazz Pharmaceuticals | GWP42006 | — | COMPLETED | 2015-10 | NCT02369471 |
| Jazz Pharmaceuticals | GWP42003-P 5 mg/kg/day Dose | — | COMPLETED | 2015-03-09 | NCT02091206 |
| UCB Pharma | Lacosamide | Voltage-gated sodium channels | COMPLETED | 2014-08 | NCT00938431 |
| SK Life Science, Inc. | YKP3089 | — | COMPLETED | 2013-06 | NCT01397968 |
| Eisai Inc. | Perampanel | Noncompetitive AMPA Glutamate Receptor Antagonist [EPC] | COMPLETED | 2013-06 | NCT01161524 |
| UCB Pharma | Brivaracetam | Epoxide Hydrolase Inhibitors [MoA] | COMPLETED | 2013-03 | NCT00422422 |
| Acorda Therapeutics | Diazepam | Benzodiazepine [EPC] | COMPLETED | 2013-02 | NCT01417078 |
| Bial - Portela C S.A. | ESL Banana taste | — | COMPLETED | 2012-12 | NCT02021461 |
| UCB BIOSCIENCES, Inc. | Lacosamide | Voltage-gated sodium channels | COMPLETED | 2012-10 | NCT01118962 |
| Novartis | BGG492 | — | COMPLETED | 2012-07 | NCT01338805 |
| Supernus Pharmaceuticals, Inc. | TPM XR | — | COMPLETED | 2012-06 | NCT01284530 |
| Bial - Portela C S.A. | Eslicarbazepine acetate (BIA 2-093) | — | COMPLETED | 2012-03 | NCT01527513 |
| UCB Japan Co. Ltd. | Levetiracetam | SV2A | COMPLETED | 2012-02 | NCT01407523 |
| Novartis | Investigational new drug, company code: BGG492 | — | COMPLETED | 2011-09 | NCT01147003 |
| UCB BIOSCIENCES, Inc. | Lacosamide | Voltage-gated sodium channels | COMPLETED | 2011-08 | NCT01118949 |
| Vertex Pharmaceuticals Incorporated | VX-765 | — | COMPLETED | 2010-11 | NCT01048255 |
| Marinus Pharmaceuticals | ganaxolone | Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator [EPC] | COMPLETED | 2010-10 | NCT01002820 |
| Novartis | BGG492 | — | COMPLETED | 2010-09 | NCT00784212 |
| Novartis | Investigational new drug, company code: BGG492 | — | COMPLETED | 2010-08 | NCT00887861 |
| UCB BIOSCIENCES, Inc. | Keppra XR | SV2A | COMPLETED | 2010-03 | NCT00961441 |
| UCB Pharma SA | Levetiracetam | SV2A | COMPLETED | 2010-03 | NCT00505934 |
| Takeda | Soticlestat | — | TERMINATED | 2025-07-30 | NCT03635073 |
| AbbVie | CVL-865 | — | TERMINATED | 2024-12-05 | NCT04686786 |
| UCB Biopharma SRL | Lacosamide intravenous | — | TERMINATED | 2024-08-06 | NCT04519645 |
| Neurocrine Biosciences | NBI-921352 | — | TERMINATED | 2024-03-11 | NCT05493293 |
| Cerebral Therapeutics LLC | — | — | TERMINATED | 2024-03-01 | NCT04153175 |
| Cerebral Therapeutics LLC | Valproic Acid delivered to ICV | — | TERMINATED | 2024-03-01 | NCT04529954 |
| Equilibre Biopharmaceuticals B.V. | EQU-001 | — | TERMINATED | 2023-07-01 | NCT05473442 |
| UCB Biopharma SRL | Padsevonil | — | TERMINATED | 2020-12-11 | NCT03370120 |
| UCB Biopharma SRL | UCB0942 | — | TERMINATED | 2020-11-24 | NCT02625090 |
| Radius Pharmaceuticals, Inc. | Cannabidiol Oral Solution | — | TERMINATED | 2019-06-24 | NCT03355300 |
| Eisai Inc. | E2082 | — | TERMINATED | 2019-06-18 | NCT03686033 |
| Radius Pharmaceuticals, Inc. | Cannabidiol Oral Solution | — | TERMINATED | 2019-05-15 | NCT03336242 |
| Eisai Inc. | E2730 | — | TERMINATED | 2019-02-14 | NCT03603639 |
| Acorda Therapeutics | diazepam nasal spray | — | TERMINATED | 2016-07 | NCT02316847 |
| Acorda Therapeutics | diazepam nasal spray | — | TERMINATED | 2016-05 | NCT02474407 |
| UCB BIOSCIENCES, Inc. | Brivaracetam intravenous solution | — | TERMINATED | 2014-10 | NCT02088957 |
| Vertex Pharmaceuticals Incorporated | VX-765 Part A | — | TERMINATED | 2013-08 | NCT01501383 |
| GSK | ezogabine/retigabine | — | TERMINATED | 2013-04-29 | NCT01494584 |
| Pfizer | ICA-105665 | — | TERMINATED | 2010-09 | NCT00979004 |
| Biohaven Therapeutics Ltd. | BHV-7000 | — | ENROLLING BY INVITATION | 2026-12 | NCT06443463 |
| Engrail Therapeutics INC | ENX-101 | — | WITHDRAWN | 2024-09 | NCT05481905 |
| MGC Pharmaceuticals d.o.o | MGCND00EP1 | — | WITHDRAWN | 2024-05-30 | NCT04406948 |
| ES Therapeutics Australia Pty Ltd | ES-481 | — | WITHDRAWN | 2021-10 | NCT04737174 |
| Novartis | BGG492 | — | WITHDRAWN | 2010-11 | NCT01167335 |
Showing 52 of 52 trials
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| Suninflam Inc | SIF001 | — | RECRUITING | 2027-01-15 | NCT07051629 |
| Actio Biosciences, Inc. | ABS-1230 | — | RECRUITING | 2026-03 | NCT07156201 |
| iQure Australia Pty Ltd | iQ-007 | — | ACTIVE NOT RECRUITING | 2026-01-29 | NCT06899230 |
| Shanghai UniXell Biotechnology Co., Ltd | UX-GIP001 | — | NOT YET RECRUITING | 2029-07-01 | NCT07572812 |
| SK Life Science, Inc. | Xcopri | Sodium Channel Antagonists [MoA] | COMPLETED | 2025-11-06 | NCT04903314 |
| NeuroPro Therapeutics, Inc. | NPT 2042 (Reference formula/Formulation 1) | — | COMPLETED | 2025-11-04 | NCT07222878 |
| Biocodex | Stiripentol capsule (Diacomit®) | — | COMPLETED | 2025-08-27 | NCT07176832 |
| NeuroPro Therapeutics, Inc. | NPT 2042 | — | COMPLETED | 2025-06-26 | NCT06525649 |
| Humanis Saglık Anonim Sirketi | Perampanel 10 MG | — | COMPLETED | 2023-11-26 | NCT06450236 |
| Humanis Saglık Anonim Sirketi | Perampanel 12 MG | — | COMPLETED | 2023-09-20 | NCT06450223 |
| NeuroPro Therapeutics, Inc. | NPT 2042 (bumetanide analog) or Matching Placebo | — | COMPLETED | 2023-03-17 | NCT05503511 |
| UCB Biopharma SRL | Alprazolam | Benzodiazepine [EPC] | COMPLETED | 2022-04-05 | NCT04857307 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | OPC-214870 | — | COMPLETED | 2021-10-11 | NCT04241965 |
| UCB Biopharma S.P.R.L. | Padsevonil | — | COMPLETED | 2019-05-18 | NCT03695094 |
| Sanofi | sodium valproate | — | COMPLETED | 2019-04-11 | NCT03681158 |
| Neurelis, Inc. | NRL-1 | — | COMPLETED | 2019-04-10 | NCT02724423 |
| Supernus Pharmaceuticals, Inc. | BIS-001 ER | — | COMPLETED | 2017-09-30 | NCT03156439 |
| Bial - Portela C S.A. | Eslicarbazepine acetate (ESL) | — | COMPLETED | 2017-01-05 | NCT03116321 |
| Takeda | TAK-935 | — | COMPLETED | 2016-04 | NCT02539134 |
| Takeda | TAK-935 | — | COMPLETED | 2015-12 | NCT02497235 |
| GSK | Lamotrigine Dispersible/Chewable tablet | — | COMPLETED | 2014-07-08 | NCT02064465 |
| Bial - Portela C S.A. | BIA 9-1067 | — | COMPLETED | 2014-04 | NCT02305329 |
| Jazz Pharmaceuticals | GWP42006 | — | COMPLETED | 2013-12 | NCT01918735 |
| GSK | Lamotrigine Dispersible/Chewable tablets 5mg*5 | — | COMPLETED | 2013-06-06 | NCT01879423 |
| GSK | 50mg Ezogabine/retigabine | — | COMPLETED | 2012-06-27 | NCT01462669 |
| GSK | Retigabine / Ezogabine | — | COMPLETED | 2012-04-24 | NCT01480609 |
| GSK | Digoxin Alone | — | COMPLETED | 2012-04-17 | NCT01583036 |
| GSK | Topiramate coated tablet | — | COMPLETED | 2011-09-11 | NCT01439438 |
| GSK | Investigational Medicinal Product (MR1) | — | COMPLETED | 2011-05-23 | NCT01332513 |
| GSK | Lamotrigine | Anti-epileptic Agent [EPC] | COMPLETED | 2011-05-23 | NCT01357902 |
| GSK | Gabapentin 300 mg | — | COMPLETED | 2011-01-22 | NCT01738893 |
| Supernus Pharmaceuticals, Inc. | Topiramate IR | — | COMPLETED | 2010-12 | NCT01114854 |
| Bial - Portela C S.A. | BIA 2-093 | — | COMPLETED | 2010-11 | NCT02284880 |
| Eisai Inc. | Perampanel and Microgynon-30 | — | COMPLETED | 2010-10 | NCT01209858 |
| Eisai Inc. | perampanel | Noncompetitive AMPA Glutamate Receptor Antagonist [EPC] | COMPLETED | 2010-09 | NCT01240187 |
| Bial - Portela C S.A. | BIA 2-093 | — | COMPLETED | 2009-11 | NCT02284854 |
| Roxane Laboratories | Oxcarbazepine | Anti-epileptic Agent [EPC] | COMPLETED | 2009-09 | NCT01702623 |
| Roxane Laboratories | Oxcarbazepine | Anti-epileptic Agent [EPC] | COMPLETED | 2009-09 | NCT01703468 |
| Bial - Portela C S.A. | Eslicarbazepine acetate | Voltage-gated sodium channels | COMPLETED | 2009-08 | NCT00987558 |
| UCB Pharma | Lacosamide | Voltage-gated sodium channels | COMPLETED | 2009-02 | NCT01450111 |
| Bial - Portela C S.A. | Eslicarbazepine acetate | Voltage-gated sodium channels | COMPLETED | 2008-12 | NCT00900237 |
| Bial - Portela C S.A. | eslicarbazepine acetate and Microginon® | — | COMPLETED | 2008-11 | NCT00898560 |
| UCB Pharma | Brivaracetam | Epoxide Hydrolase Inhibitors [MoA] | COMPLETED | 2008-10 | NCT00736931 |
| GSK | lamotrigine | Anti-epileptic Agent [EPC] | COMPLETED | 2008-09-12 | NCT00627575 |
| GSK | Lamotrigine tablet | — | COMPLETED | 2008-03-06 | NCT00605371 |
| Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | paliperidone ER | — | COMPLETED | — | NCT01060228 |
| Receptor Life Sciences | High dose RLS103 | — | TERMINATED | 2024-02-23 | NCT05678881 |
| H. Lundbeck A/S | Lu AG06466 | — | TERMINATED | 2022-04-14 | NCT05081518 |
| NeuroVista Corporation | — | — | TERMINATED | 2012-08 | NCT01043406 |
| Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. | Brivaracetam Oral Solution (Test Formulation) | — | ENROLLING BY INVITATION | 2024-12-31 | NCT06762743 |
| UCB Biopharma SRL | Padsevonil type 1 Tablet 200 mg | — | WITHDRAWN | 2020-05-22 | NCT04283136 |
| GSK | Retigabine | — | WITHDRAWN | 2012-10-18 | NCT01691872 |
Novel Drugs by Company (New molecular entities)
Reformulations (11 drugs) Click to expand
Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.
FINTEPLA
UCB INC
T3 2020
VALTOCO
NEURELIS INC
T3 2020
NAYZILAM
UCB INC
T3 2019
SYMPAZAN
ASSERTIO SPECLTY
T3 2018
ONFI
LUNDBECK PHARMS LLC
T1 2011
SUPREP BOWEL PREP KIT
AZURITY
T4 2010
AFINITOR
Novartis
T1 2009
BANZEL
EISAI INC
T1 2008
DIASTAT ACUDIAL
BAUSCH
T3 1997
CEREBYX
PARKE DAVIS
T1 1996
TIS-U-SOL IN PLASTIC CONTAINER
Baxter
T5 1981
Drug Targets
Generic Drugs (9 ANDA approved) Click to expand
Generic drugs contain the same active ingredient as the brand-name drug and are approved via ANDA (Abbreviated New Drug Application).
Drug Categories:
- Novel Drugs: NDA Type 1/2 (new molecular entity) or original BLA
- Reformulations: NDA Type 3/5 (new dosage form of existing molecule)
- Biosimilars: BLA-approved biologics highly similar to reference products
- Generics: ANDA-approved copies of small molecule drugs